LadRx Corporation
LadRx Corporation, a biopharmaceutical company, engages in research and development of chemotherapeutic drugs for solid tumors in the United States. The company offers linker activated drug releases (LADR) technology, a platform consists of an organic backbone that is attached to a chemotoxic agent that targets and delivers the chemotoxic agent to the tumor environment and release within the tumo… Read more
LadRx Corporation (LADX) - Total Assets
Latest total assets as of March 2025: $260.07K USD
Based on the latest financial reports, LadRx Corporation (LADX) holds total assets worth $260.07K USD as of March 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
LadRx Corporation - Total Assets Trend (2018–2024)
This chart illustrates how LadRx Corporation’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
LadRx Corporation - Asset Composition Analysis
Current Asset Composition (December 2024)
LadRx Corporation's total assets of $260.07K consist of 99.7% current assets and 0.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 90.5% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how LadRx Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: LadRx Corporation's current assets represent 99.7% of total assets in 2024, an increase from 98.2% in 2018.
- Cash Position: Cash and equivalents constituted 90.5% of total assets in 2024, down from 93.2% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
LadRx Corporation Competitors by Total Assets
Key competitors of LadRx Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
LadRx Corporation - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - LadRx Corporation generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - LadRx Corporation is currently not profitable relative to its asset base.
LadRx Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.11 | 1.18 | 5.94 |
| Quick Ratio | 0.11 | 1.18 | 5.94 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-2.14 Million | $ 339.08K | $ 13.76 Million |
LadRx Corporation - Advanced Valuation Insights
This section examines the relationship between LadRx Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.94 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | -63.6% |
| Total Assets | $839.51K |
| Market Capitalization | $49.51K USD |
Valuation Analysis
Below Book Valuation: The market values LadRx Corporation's assets below their book value (0.06 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: LadRx Corporation's assets decreased by 63.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for LadRx Corporation (2018–2024)
The table below shows the annual total assets of LadRx Corporation from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $839.51K | -63.62% |
| 2023-12-31 | $2.31 Million | +2.72% |
| 2022-12-31 | $2.25 Million | -74.25% |
| 2021-12-31 | $8.73 Million | -27.64% |
| 2020-12-31 | $12.06 Million | -30.11% |
| 2019-12-31 | $17.26 Million | -24.74% |
| 2018-12-31 | $22.93 Million | -- |